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Abstract 
Confusion and controversy exist regarding the cardiovascular effects of dietary supplements 
containing caffeine and Citrus aurantium (bitter orange) extract. The primary protoalkaloidal 
ingredient in bitter orange extract is p-synephrine which has some structural similarities to 
ephedrine and nor-epinehrine, but exhibits markedly different pharmacokinetic and receptor 
binding properties. The goal of this study was to investigate the cardiovascular effects of a 
product containing caffeine, bitter orange extract (p-synephrine) and green tea extract in 
mildly overweight individuals. Fourteen female and nine male subjects (age 24.7 +7.4 yrs, BMI: 
26.6 +3.8) volunteered in this randomized, placebo-controlled, crossover, double-blind de-
signed study. On day one, subjects entered the laboratory following an overnight fast. Heart 
rate and blood pressure were recorded at 60 min. Expired air was analyzed for the next 10 
min of the session. At each of three meals, subjects ingested one capsule that was either a 
non-caloric placebo or a dietary supplement that contained 13 mg p-synephrine and 176 mg 
caffeine. On the following day, the subjects returned and repeated the protocol for data 
collection beginning 60 min after consuming one capsule of the placebo or the dietary sup-
plement. No effects of the dietary supplement on heart rate, systolic and diastolic blood 
pressure or mean arterial pressure were observed. No between or within group differences 
were observed when data were analyzed for gender and caffeine usage. A small but significant 
decrease in resting respiratory exchange ratio was observed for the low caffeine user group in 
response to the product containing caffeine and p-synephrine. The results of this study in-
dicate that ingestion of a product containing bitter orange extract, caffeine and green tea 
extract does not lead to increased cardiovascular stress and that fat oxidation may increase in 
certain populations. 
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Introduction 
Approximately two-thirds of the adult American 
population are overweight while about one-third is by 
definition considered to be obese [1]. The increase in 
obesity is associated with increased incidences of di-
abetes, hypertension, hyperlipidemias, cardiovascular 
diseases,  stroke,  and  premature  deaths  at  a  cost  of 
billions of dollars annually [2, 3]. As a consequence, 
great emphasis is being placed on various approaches Int. J. Med. Sci. 2011, 8 
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to  weight  loss  and  weight  management,  including 
dietary supplements, diets, and exercise programs.  
 Citrus aurantium (bitter  orange)  extract  and  its 
primary protoalkaloidal constituent p-synephrine are 
widely used in weight loss and weight management 
products in combination with caffeine, polyphenolics, 
and other constituents [4-7]. These products are de-
signed  to  promote  thermogenesis  and  increase  me-
tabolism, suppress appetite, and/or slow the absorp-
tion of fats and carbohydrates [5]. 
 In spite of their widespread use and the lack of 
credible  reports  regarding  adverse  effects,  contro-
versy has existed regarding the safety of bitter orange 
extract  and  p-synephrine  [8-11].  The  safety  of 
p-synephrine is clouded by its structural similarity to 
nor-epinephrine in spite of the fact that the pharma-
cokinetics  of  the  two  compounds  and  the  receptor 
binding specificities are vastly different due to signif-
icant structural differences [5, 12]. Furthermore, there 
is a lack of understanding [8, 10] between the phar-
macological  properties  of  p-synephrine  (hydroxyl 
group on the para position of the benzene ring) which 
is  found  in  C.  aurantium,  and  m-synephrine  (phe-
nylephrine; with the hydroxyl group on the meta po-
sition) which is used in nasal decongestants and is not 
a constituent of C. aurantium.  
 Because of the known cardiovascular effects of 
nor-epinephrine and ephedrine, it has generally been 
assumed that consumption of p-synephrine and bitter 
orange extract will likewise result in increases in heart 
rate and blood pressure [8-11]. The purpose of this 
study was to determine the effects of the acute ad-
ministration  of  a  product  containing  caffeine  from 
guarana, p-synephrine from C. aurantium and a green 
tea  polyphenolic  extract  on  heart  rate  and  blood 
pressure in mildly overweight human subjects. 
Methods 
 Twenty-three subjects volunteered to participate 
in  this  double  blind,  placebo  controlled  cross-over 
study. Fourteen subjects were female and nine were 
male. Table 1 summarizes the characteristics of these 
subjects.  The  Institutional  Review  Board  approved 
this study prior to data collection. All subjects com-
pleted  a  health  history  questionnaire  and  provided 
informed consent prior to participation. 
An  uninvolved  individual  randomly  divided 
subjects  into  two  groups,  12  and  11  subjects  per 
group. The subjects received either the experimental 
product in capsule form or a non-caloric placebo in a 
cross-over  design.  Following  data  collection,  a  one 
week washout period was provided between the two 
experimental procedures. Each capsule of the exper-
imental treatment product (Acceleron®) contained C. 
aurantium  extract  (AdvantraZ®,  6%  p-synephrine 
yielding 13 mg p-synephrine), 176 mg caffeine in the 
form of guarana extract, and 55.5 mg of green tea ex-
tract  with  small  amounts  of  other  ingredients  (see 
Table 2). While on the experimental treatment, each 
subject consumed four capsules for a total of 52 mg 
p-synephrine and 704 mg caffeine over a 24 hour pe-
riod. 
 
Table 1. Subject characteristics 
  Age 
(yrs) 
 Height 
(m) 
 Weight 
(kg) 
 BMI 
Overall  24.5 ± 7.4  1.74 ± 0.09  81.1 ± 17.1  26.6 ± 3.8 
Females 
(n=14) 
25.4 ± 9.3  1.68 ± 0.07  72.4 ± 11.8  25.5 ± 3.2 
Males (n=9)  23.1 ± 2.5  1.82 ± 0.06  94.5 ± 15.7  28.3 ± 4.1 
BMI: Body mass index. Each value is the mean + SD. 
 
Table 2. Dietary supplement ingredients per capsule 
Ingredient  Amount 
Guarana (caffeine)  176 mg 
Citrus aurantium (p-synephrine)  13 mg 
Green Tea Powder Extract  55.5 mg 
Bee Pollen  1 mg  
White Willow Bark Powder  1 mg 
Panax ginseng Root  2 mg 
Garcinia cambogia extract  2 mg 
Vanadium 
 
0.15 mcg 
 
 
 
On a given treatment, day one was used to col-
lect baseline data. All subjects were instructed to re-
frain from exercise 24 hours before their trial. Dietary 
intake was not controlled, but subjects were instruct-
ed to maintain a consistent intake from trial to trial. 
Subjects  entered  the  laboratory  on  the  scheduled 
morning following an overnight (12 hour) fast. They 
sat quietly for 30 min in a comfortable chair in a room 
with dim light.  
Expired air was collected for 10 min from 20 to 
30 min of this session as subjects breathed through a 
one-way breathing valve. Expired air was collected in 
Douglas  bags  and  contents  measured  by  Ametek 
Oxygen  and  Carbon  Dioxide  Analyzers  (Thermox, 
Pittsburgh, PA) while volume was measured using a 
Tissot  spirometer.  Indirect  calorimetry  was  used  to 
determine oxygen uptake (VO2) and carbon dioxide 
production  (VCO2).  The  non-protein  respiratory  ex-
change  ratio  (RER)  value  was  calculated  from  VO2 
and VCO2. The RER was used as an index of fat and 
carbohydrate oxidation. Heart rate (Polar HR Moni-Int. J. Med. Sci. 2011, 8 
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tor,  Stamford,  CT)  and  blood  pressure  (ausculatory 
method) were collected at 30 min.  
Following baseline data collection, subjects were 
given three treatment capsules and instructed to in-
gest  one  capsule  with  each  meal  during  that  day. 
Subjects returned to the laboratory on the following 
morning after an overnight fast and were given the 
fourth treatment capsule with water. Subjects then sat 
quietly for 60 min. The 60 min period was estimated 
to give maximal blood levels of the ingredients [11, 
13].  Expired  air  was  then  collected  and  analyzed 
during the next 10 min of the session. Heart rate and 
blood pressure were recorded at the end of expired air 
collection, approximately 72-75 min after capsule in-
gestion.  
Three analyses of the data were performed using 
2 x 2 analysis of variance (ANOVA). For the first data 
analysis,  treatment  and  time  were  the  independent 
factors using all 23 subjects. The second analysis sep-
arated  and  analyzed  the  data  according  to  gender. 
The third analysis assessed the data for differences in 
high  caffeine  and  low-caffeine  users.  Fourteen  sub-
jects were classified as low caffeine users and nine as 
high caffeine users, employing the breakpoint of 150 
mg caffeine per day to separate the two groups. Sta-
tistical significance was established at p<0.05. All data 
are reported as mean + standard deviation (SD). 
Results 
 All 23 subjects completed the study. Based on 
self-report and questionnaire, all subjects ingested the 
given capsules on time as noted in the Methods sec-
tion. No adverse treatment effects were observed or 
reported by any of the subjects. 
Table 3 contains the cardiovascular data from the 
entire  subject  population.  No  statistical  differences 
were observed within groups or between groups for 
any of the measures. Heart rate, blood pressure, and 
metabolic variables were maintained from baseline to 
the  post-ingestion  collection  period  regardless  of 
treatment. Three subjects (one male and two females) 
were pre-existing hypertensives (systolic blood pres-
sure > 140 mm Hg). Blood pressures for the hyper-
tensive  individuals  did  not  change  significantly  in 
response to the dietary supplement. 
Table 4 contains data separated by gender. No 
significant  differences  were  observed  for  the  de-
pendent  variables  in  the  female  group.  Likewise, 
males  did  not  demonstrate  significant  differences 
when the dietary supplement was ingested. 
Data separated into high and low caffeine users 
are presented in Table 5. As with the previous anal-
yses,  no  significant  differences  were  observed  for 
heart  rates  or  blood  pressures  between  the  experi-
mental and placebo control groups. However, there 
was a small but significant change in RER data for the 
low caffeine users relative to both the placebo control 
group and the pre-treatment baseline for the low caf-
feine group. After ingestion of dietary supplement the 
low caffeine users exhibited a decrease in RER from 
0.84 + 0.05 to 0.81 + 0.04. 
Effect sizes were calculated for each of the anal-
yses where data were separated by gender (Table 4) or 
caffeine consumption (Table 5). The effects based on 
number of subjects per group were all below 0.4, in-
dicating low to moderate influence. 
 
Table 3. The effects of supplementation on cardiovascular 
and metabolic parameters (n=23) 
Treatment  Heart 
Rate 
(bpm) 
 Systolic 
BP  (mm 
Hg) 
 Diastolic 
BP  (mm 
Hg)  
MAP 
(mm 
Hg)  
RER 
PL pre  62.4 
±11.8 
119.9 
±12.0 
77.7 ± 8.9  91.8 ± 
9.1 
0.85 
±0.07 
PL post  60.7 
±12.5 
118.7 
±10.2 
76.7 ± 7.8  90.7 ± 
8.5 
0.86 
±0.05 
DS pre  63.5 
±14.2 
119.2 
±14.3 
76.9 ± 8.4  91.0 ± 
9.8 
0.85 
±0.06 
DS post  60.9 
±12.4 
118.9 
±11.1 
79.2 ± 6.4  92.4 ± 
7.3 
0.83 
±0.07 
PL: Placebo; DS: Dietary Supplement; BP: Blood Pressure; MAP: 
Mean Arterial Pressure; RER: Respiratory Exchange Ratio. Each 
value is the mean +SD. 
 
Table 4. The effect of gender and supplementation on 
cardiovascular and metabolic parameters 
Treatment  Heart 
Rate 
(bpm) 
 Systolic 
BP  (mm 
Hg) 
 Diastolic 
BP  (mm 
Hg)  
MAP 
(mm 
Hg)  
RER 
A. Females 
(n=14) 
 
         
PL pre  65.9 
±13.2 
117.9 
±12.6 
76.3 
±10.5 
90.1 
±10.4 
0.86 
±0.08 
PL post  65.1 
±13.1 
117.2 
±12.6 
76.1 ±8.9  89.8 
±9.5 
0.85 
±0.05 
DS pre  70.2 
±13.8 
112.8 
±12.4 
74.2 ±8.8  87.1 
±9.4 
0.84 
±0.05 
DS post  65.5 
±12.4 
116.2 
±10.3 
79.4 ±5.9  91.7 
±7.0 
0.82 
±0.09 
B. Males 
(n=9) 
         
PL pre  56.9 
±6.3 
123.0 
±11.0 
80.0 ±5.2  94.3 
±6.4 
0.85 
±0.05 
PL post  53.9 
±8.0 
120.9 
±11.9 
77.7 ±6.3  92.1 
±7.2 
0.86 
±0.05 
DS pre  53.1 
±7.0 
128.1 
±11.4 
91.0 ±6.2  97.1 
±7.3 
0.85 
±0.06 
DS post  53.8 
±8.8 
123.0 
±11.6 
78.8 ±7.5  93.5 
±8.0 
0.83 
±0.05  
 PL: Placebo; DS: Dietary Supplement; BP: Blood Pressure; MAP: 
Mean Arterial Pressure; RER: Respiratory Exchange Ratio. Each 
value is the mean + SD. Int. J. Med. Sci. 2011, 8 
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Table 5. The effects of caffeine use and supplementation on 
physiological responses. 
Treatment  Heart 
Rate 
(bpm) 
 Systolic 
BP  (mm 
Hg) 
 Diastolic 
BP  (mm 
Hg)  
MAP 
(mm 
Hg)  
RER 
A. Low 
Caffeine 
Users 
(n=14) 
         
PL pre  63.4 
±11.9 
120.6±12.1  79.8 ±9.6  93.4 
±9.7 
0.84 
±0.06 
PL post  63.4 
±13.1 
117.9±12.7  78.1 ±8.2  91.3 
±8.9 
0.84 
±0.04 
DS pre  65.8 
(15.2 
119.4±13.6  77.9 ±9.2  91.8 
±10.3 
0.84 
±0.05 
DS post  64.7 
(13.7 
120.6±11.1  80.6 ±6.3  94.0 
±7.3 
0.81 
±0.04* 
B. High 
Caffeine 
Users 
(n=9) 
         
PL pre  60.9 
±12.1 
118.8 ±12.5  74.6 ±7.0  89.3 
±8.1 
0.87 
±0.09 
PL post  56.7 
±10.9 
119.8 ±12.2  74.7 ±7.2  89.7 
±8.3 
0.88 
±0.06 
DS pre  60.0 
±12.6 
118.9 ±16.2  75.2 ±7.2  89.8 
±9.5 
0.86 
±0.06 
DS post  55.0 
±7.3 
116.1 ±11.1  76.9 ±6.2  90.0 
±7.0 
0.86 
±0.10  
*Significantly different from pre-ingestion value and placebo 
groups (P<0.05). 
PL: Placebo; DS: Dietary Supplement; Heart Rate; BP: Blood Pres-
sure; MAP: Mean Arterial Pressure; RER: Respiratory Exchange 
Ratio. Each value is the mean +SD. 
  
Discussion 
The results of this study indicate that acute in-
gestion of a dietary supplement containing caffeine, 
bitter  orange  extract  (p-synephrine)  and  green  tea 
extract did not lead to significant cardiovascular ef-
fects  as  reflected  by  blood  pressure  and  heart  rate, 
regardless of treatment or subject grouping either by 
gender or caffeine usage. Subjects in the present study 
ingested 39 mg of p-synephrine and 528 mg of caffeine 
the  day  before  testing  followed  by  ingestion  of  an 
additional 13 mg p-synephrine and 176 mg caffeine 
the next morning after an overnight fast. This protocol 
more closely represents typical ingestion regimes of 
dietary supplements used for weight loss and weight 
management,  and  is  unique  as  compared  to  other 
studies that involve only a single dose [11, 13-15].  
Controversy exists regarding the cardiovascular 
effects  of  C.  aurantium  extract  in  combination  with 
caffeine,  and  various  authors  make  the  assumption 
that an increase in heart rate and blood pressure are to 
be  expected  [8,  10,  16-19].  However,  a  number  of 
studies that have assessed the cardiovascular effects 
of products composed of C. aurantium extract in com-
bination with caffeine and other ingredients have not 
observed an increase in blood pressure [6, 7, 11, 19-21] 
or heart rate [ 6, 7, 19-21]. The results of the present 
study clearly agree with these previous observations. 
Haller  et  al.  [11]  examined  the  cardiovascular 
effects  associated  with  a  single  dose  of  a  mul-
ti-component dietary supplement (Xenadrine®) in 10 
subjects.  The  supplement  contained  5.5  mg 
p-synephrine, 239 mg caffeine, 5.7 mg octopamine and 
undisclosed  amounts  of  other  ingredients  including 
catechin polyphenols. The hemodynamic effects of a 
single dose of a C. aurantium extract (Advantra Z®) 
that  contained  46.9  mg  p-synephrine  were  also  ex-
amined.  The  results  demonstrated  that  the  dietary 
supplement, but not the p-synephrine-containing bit-
ter orange extract, increased both systolic and dias-
tolic blood pressures at two hours post treatment rel-
ative  to  the  control  group.  No  significant  effects  of 
either treatment on heart rate were noted over the first 
three hours after ingestion of the products. However, 
a significant increase in heart rate over control was 
noted at the six hour time point. 
This study of Haller et al. [11] is complicated by 
the fact that all subjects consumed a meal three hours 
after treatment ingestion. After eating, an increase in 
heart rate occurred in all three treatment groups. The 
increase  in  heart  rate  does  not  coincide  with  the 
pharmacokinetics including blood levels and half–life 
of p-synephrine [11, 13], but does coincide with the 
thermic  effect  of  food  in  this  study.  Given  that  the 
control group responded similarly to the two treat-
ment groups after the meal at the four and eight hour 
measurements (one and five hours after the meal), the 
reason for the apparently significant difference seen at 
only  the  six  hour  time  point  (three  hours  after  the 
meal) is unclear. No explanation is given by the au-
thors for this change in heart rate. Gougeon et al. [19] 
reported that the thermic effect of food increased by 
29%  in  17  females  after  they  ingested  26  mg 
p-synephrine. The thermic effect of p-synephrine was 
greater in males than females in the absence of a meal, 
and no significant changes occurred in pulse rates or 
blood pressures when compared with baseline values.  
Haller et al. [13] have also examined the effects, 
under  resting  and  exercise  conditions,  of  a  dietary 
supplement designed to enhance athletic performance 
in  10  subjects.  The  product  (Ripped  Fuel  Extreme 
Cut®) contained 21 mg p-synephrine, 304 mg caffeine, 
as  well  as  extracts  of  green  tea,  ginger  root,  cocoa 
seed, willow bark and wasabi. The placebo or product 
was taken one hour before 30 min of moderately in-
tense exercise. There were no treatment- related dif-
ferences  in  post-exercise  heart  rate,  systolic  blood 
pressure  or  body  temperature.  A  significant  prod-Int. J. Med. Sci. 2011, 8 
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uct-related  increase  in  diastolic  blood  pressure  (8.7 
mm Hg) was observed, apparently counteracting the 
vasodilatory  effects  of  exercise.  Due  to  the 
poly-herbal, poly-alkaloidal and poly-protoalkaloidal 
nature of this product, the ingredient or ingredients 
responsible for the observed effect cannot be deter-
mined. 
Bui et al. [15] conducted a study on 15 healthy 
subjects given a single oral dose of 900 mg bitter or-
ange  extract  (Nature’s  Way)  that  contained  6  % 
p-synephrine  (54  mg  p-synephrine)  or  the  placebo. 
Small but significant increases were observed in heart 
rate, and systolic and diastolic blood pressures for up 
to five hours. Of interest is the fact that Min et al. [18] 
used this same product in a similarly designed study 
and saw no effect in 18 subjects on systolic or diastolic 
blood  pressure,  or  on  the  rate-corrected  QT  (QTc) 
interval. 
The confusion regarding the purported cardio-
vascular effects of C. aurantium has been due, at least 
in part, to a lack of understanding of the differences in 
the pharmacokinetic and pharmacological properties 
between  p-synephrine  and  m-synephrine  (phe-
nylephrine). Failure to differentiate the effects of the 
two isomers has resulted in a number of authors at-
tributing the effects of m-synephrine to p-synephrine 
[see for example 8, 10, 17, 18, 21]. p-Synephrine (hy-
droxyl group in the para position on the benzene ring) 
is the isomeric form found in C. aurantium (bitter or-
ange).  m-Synephrine  (hydroxyl  group  in  the  meta 
position) is not a constituent of bitter orange nor is it 
present in standardized C. aurantium reference mate-
rials [22]. The m-synephrine (phenylephrine) is read-
ily available as an over-the-counter nasal decongest-
ant, is also used as an ophthalmic product for mydri-
asis, and is known for its cardiovascular effects [23]. 
The differences in pharmacological properties of 
the m- and p- isomers of synephrine can be explained 
on the basis of adrenergic receptor binding. It is well 
known  that,  in  general,  binding  to  α-adrenergic  re-
ceptors  results  in  vasoconstriction,  with  increased 
cardiovascular contractility and increased heart rate 
occurring  in  response  to  β1-adrenergic  receptor 
binding, while bronchodilation occurs in response to 
β2-adrenergic  receptor  binding  [24].  Activation  of 
β3-adrenoreceptors is believed to be associated with 
lipolysis and thermogenesis, and not adverse cardio-
vascular effects [25]. The belief that p-synephrine ex-
erts its effects by binding primarily to this receptor is 
supported by experimental [26] and receptor binding 
studies [27]. 
The cardiovascular effects of caffeine are known 
to depend on the extent of regular exposure [28, 29]. 
Caffeine–naïve subjects can experience an increase in 
blood pressure and heart rate, while regular users of 
caffeine-containing  products  develop  a  tolerance  to 
these effects. In this study, even the low caffeine users 
did not demonstrate an increase in these cardiovas-
cular  effects.  The  observation  that  the  low  caffeine 
intake group showed a reduction in RER may be a 
reflection of caffeine sensitivity. Caffeine is known to 
increase  fat  oxidation  (lower  RER),  and  this  group 
may have been more responsive to the caffeine in the 
product. 
Although  the  number  of  subjects  used  in  this 
study  is  not  large  (n=23),  this  number  exceeds  the 
number  of  subjects  used  in  frequently  referenced 
studies involving bitter orange extract. For example, 
Haller et al. [11, 13] used 10 subjects in each study, 
while Sale et al.[20] used 20 subjects, Bui et al. [15] 
used 15 subjects and Min et al. [14] used 18 subjects. 
Furthermore, as noted in the results, because of the 
small numbers of subjects when the data were sepa-
rated based on gender and caffeine intake, size effects 
were calculated for each of these analyses. The effects 
of size were low (0.2) for gender and moderate (0.4) 
for the low caffeine users with respect to RER. 
In  summary,  the  results  of  this  study  indicate 
that ingestion of a product containing bitter orange 
extract (p-synephrine), caffeine and green tea extract 
in a short-term dosing schedule similar to that com-
monly used with dietary supplements did not result 
in alterations in heart rate or blood pressure. Howev-
er,  longer  term  studies  are  required  to  assess  these 
effects under conditions similar to those encountered 
when using the product in conjunction with a long 
term weight loss program. 
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